Wellgistics Health Inc

This management proposal requests shareholder approval to amend the company’s Certificate of Incorporation to change its corporate name from Wellgistics Health, Inc. to Vantix Health Inc. Management explains the change is intended to better align the corporate identity with the company’s positioning as a healthcare-technology and pharmaceutical services platform and to create a clearer, more cohesive brand as the company executes a ‘‘micro health ecosystem’’ strategy. The Board has unanimously approved and recommends the change, noting the name change will not affect corporate status, shareholder rights, outstanding stock certificates, trading, financial statements, or SEC reporting obligations. The company indicates the new name could be accompanied by a Nasdaq ticker change to “MEDS” if Nasdaq approves. The board frames the change as a marketing and identity alignment move rather than a substantive corporate governance or financial transaction. There are no dissenters’ appraisal rights under Delaware law for a name change, and no exchange of certificates is required solely because of the name change. From a governance and investor perspective, the change is low risk operationally but can be material for brand recognition, investor communications, and market perception; shareholders should weigh brand/strategic rationale against the immateriality to economic rights. The Board’s recommendation rests on strategic and marketing grounds rather than transactional or financial necessity, and management expects to file the Certificate of Amendment promptly if approved.

This management proposal asks shareholders to approve an amendment authorizing 10,000,000 shares of blank-check preferred stock by amending the Certificate of Incorporation. Management and the Board argue that having blank-check preferred stock available provides maximum strategic and financial flexibility for future transactions, including structuring financings, facilitating acquisitions, or other corporate actions without needing immediate further shareholder approval for the specific terms. The filing explains that the Board would have discretion to create series with different preferences, rights, and conversion features, which could affect dividend, liquidation, and voting priorities. The Board acknowledges potential anti-takeover effects—such as dilution of activist or hostile bidders’ holdings or issuance to supporters—but states the amendment is driven by business and financial considerations and not intended specifically to deter change-of-control attempts. The company currently has no designated series or immediate plans to issue preferred stock, so the proposal’s effects are prospective and contingent on future Board action. Economically, future issuances could dilute existing common holders’ economic and voting stakes and potentially depress the common stock price if issued at below-market prices or convertible into common stock. Shareholders should assess the trade-off between management flexibility to execute strategic transactions and the dilution and governance risks that blank-check preferred authority can entail. Given the Board’s unanimous recommendation, management views the authorization as a prudent governance step to maintain optionality for the company’s anticipated growth.

This management proposal seeks shareholder approval to amend the company’s Amended and Restated 2023 Equity Incentive Plan to increase the aggregate share reserve by 56,493,936 shares (raising the initial limit to 100,000,000 shares per the Amendment) and to change the plan’s automatic annual increase mechanism so that beginning January 1, 2027 the plan may increase annually by up to ten percent (10%) of outstanding shares instead of the current three percent (3%). The Board frames the request as necessary to support anticipated hiring, retention, and multi-year equity compensation needs tied to the company’s expected growth, capital structure evolution, and strategic initiatives. Management highlights that awards typically vest over time and may be performance-based, and that the Administrator retains discretion over actual annual increases to manage dilution. The filing quantifies the Share Increase as approximately 45% of outstanding shares as of the record date, which represents a significant potential dilution if fully granted and issued; the Board considered dilution and believes the benefits of equity compensation—conserving cash, aligning employee interests, and competitiveness in talent markets—outweigh dilution risks. The proposal includes customary governance safeguards such as Administrator discretion and adjustment provisions for corporate transactions, but also grants considerable potential issuance authority that could materially affect shareholder ownership percentages, voting power, and EPS. Shareholders should evaluate the company’s historical equity usage, hiring plans, projected growth, and governance controls on award timing and size when considering the trade-offs. The Board’s unanimous recommendation underscores management’s view that the amendment is critical for executing its strategic plan, but the magnitude of the increase warrants close scrutiny of future grant practices and potential anti-dilution measures.